Streetbeat News

Revenues

WBS

11 analysts have recently evaluated Webster Financial Corp (NYSE:WBS), showing a mix of bullish and bearish sentiments with an average 12-month price target of $61.64, up from $56.25. The company faces challenges with a -9.9% revenue decline and below-industry market capitalization but excels in net margin, ROE, and ROA. Analysts' ratings range from 'Overweight' to 'Outperform', with several price target adjustments reflecting their changing views on the company's performance.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 5:00 pm

KGS

Kodiak Gas Services (NYSE:KGS) has received mixed analyst ratings over the past quarter, with recent evaluations showing a slight bullish trend. The average 12-month price target for KGS has been raised to $25.8, indicating a 3.2% increase from the previous target. Analysts from firms like RBC Capital, Stifel, JP Morgan, Raymond James, and Truist Securities have updated their ratings and price targets, reflecting changes in market dynamics and company performance. Kodiak Gas Services, known for its contract compression infrastructure operations in the U.S., has shown notable revenue growth of 26.47% over the past 3 months, a strong net margin of 9.42%, but faces challenges with below-average ROE and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 5:00 pm

ARKK

IYW

NVDA

SPRX

Ivana Delevska, founder of Spear Invest, is being compared to Cathie Wood due to her fund, Spear Alpha ETF (SPRX), outperforming ARK Innovation ETF (ARKK). While ARKK has seen significant outflows and flat performance in 2024, SPRX has surged 15% in the same period. Delevska's investment strategy, focusing on value and 'boots on the ground' research, contrasts with Wood's thematic approach. Delevska's success, especially in tech sectors like cybersecurity and semiconductors, has drawn attention and increased SPRX's AUM significantly.

Portfolio Pulse from Johnny Rice

March 08, 2024 | 4:23 pm

TROW

Eight analysts have recently updated their ratings on T. Rowe Price Gr (NASDAQ:TROW), with a mix of indifferent, somewhat bearish, and bearish views. The average 12-month price target for TROW has been raised to $101.62, indicating a positive shift in sentiment. The company has shown impressive revenue growth and strong financial health indicators such as ROE and ROA, despite a below-average net margin and market capitalization. Analysts' adjustments to ratings and price targets reflect their response to market conditions and TROW's performance.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 4:01 pm

MLM

Recent analyst ratings for Martin Marietta Materials (NYSE:MLM) show a positive outlook, with 8 analysts offering varied opinions over the last three months. The average 12-month price target has been raised to $597.88, marking a 14.69% increase from the previous target of $521.29. Analysts from firms like HSBC, Stephens & Co., and Goldman Sachs have raised their price targets, reflecting optimism about the company's performance. Martin Marietta, a leading producer of construction aggregates, has shown strong financial performance with significant revenue growth, high net margin, and impressive ROE and ROA, despite a higher debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 4:00 pm

WTFC

Analyst ratings for Wintrust Financial (NASDAQ:WTFC) have varied over the last quarter, with a recent shift towards more bullish sentiments. The average 12-month price target has increased to $113.0, up 12.25% from the previous $100.67, indicating a positive outlook. Recent analyst actions include upgrades and maintenance of positive ratings, with price targets ranging from $105.00 to $135.00. Wintrust Financial, a financial holding company, has shown solid financial performance, including a 3.19% revenue growth rate and a notable net margin of 20.41%. However, its debt-to-equity ratio of 0.73 suggests a higher financial risk.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 4:00 pm

PSX

Five analysts have recently updated their ratings on Phillips 66 (NYSE:PSX), with a shift towards a more bullish outlook. The average 12-month price target for PSX has been raised to $153.2, reflecting a 6.98% increase from the previous target of $143.20. Analysts from firms including Piper Sandler, Barclays, Wells Fargo, and Raymond James have raised their price targets, indicating a positive sentiment towards the company's performance. Despite a -4.99% decline in revenue growth for the last quarter of 2023 and the closure of the Rodeo, California refinery, Phillips 66's financial indicators such as net margin, ROE, and ROA remain strong, surpassing industry benchmarks.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 4:00 pm

LLY

The analysis compares Eli Lilly (LLY) against its competitors in the Pharmaceuticals industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Eli Lilly shows a premium valuation with high P/E, P/B, and P/S ratios, a strong ROE, and significant revenue growth, but its EBITDA and gross profit are below the industry average. The company's higher debt-to-equity ratio indicates increased financial risk.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 4:00 pm

PBR

Shares of Petroleo Brasileiro S.A. (PBR) are trading lower after the company reported a mixed fourth-quarter financial performance. While sales exceeded consensus, oil products revenue and domestic market revenues declined. Adjusted EBITDA and earnings per ADS fell short of expectations, despite an increase in oil and natural gas production. The company also reported higher capex and net debt.

Portfolio Pulse from Lekha Gupta

March 08, 2024 | 3:34 pm

ABBV

BGNE

GILD

NVS

RHHBY

The FDA granted accelerated approval to BeiGene Ltd's Brukinsa, in combination with Roche Holdings AG's Gazyva, for adult patients with relapsed or refractory follicular lymphoma, marking its fifth indication in the U.S. This approval is based on the response rate and durability from the ROSEWOOD Phase 2 trial. Brukinsa's global sales reached $1.3 billion for the full year 2023, with peak annual sales estimated to be $3 billion to $4 billion. BGNE shares rose 0.94% following the announcement.

Portfolio Pulse from Vandana Singh

March 08, 2024 | 3:02 pm